ProShares UltraShort NASDAQ Biotechnology
8 hedge funds and large institutions have $3.51M invested in ProShares UltraShort NASDAQ Biotechnology in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
2.02% less ownership
Funds ownership: 5.55% → 3.53% (-2%)
51% less capital invested
Capital invested by funds: $7.11M → $3.51M (-$3.6M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
8
Holding in Top 10
–
Calls
$560K
Puts
$211K
Top Buyers
| 1 | +$1.44M | |
| 2 | +$332K | |
| 3 | +$319K | |
| 4 |
HF
HRT Financial
New York
|
+$228K |
| 5 |
Morgan Stanley
New York
|
+$5.81K |
Top Sellers
| 1 | -$3.45M | |
| 2 | -$979K | |
| 3 | -$918K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$68.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$18.7K |